News stories about Neos Therapeutics (NASDAQ:NEOS) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Neos Therapeutics earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 44.2275365352486 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Neos Therapeutics (NEOS) Earns “Buy” Rating from Cowen (americanbankingnews.com)
- When Will Neos Therapeutics Inc (NASDAQ:NEOS) Turn A Profit? (finance.yahoo.com)
- Zacks Investment Research Upgrades Neos Therapeutics (NEOS) to Hold (americanbankingnews.com)
- Neos Therapeutics (NEOS) PT Set at $20.00 by Cantor Fitzgerald (americanbankingnews.com)
Several analysts have issued reports on the company. BidaskClub raised Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, March 10th. Cantor Fitzgerald set a $20.00 price target on Neos Therapeutics and gave the company a “buy” rating in a research note on Thursday, March 15th. Zacks Investment Research downgraded Neos Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 25th. Wells Fargo set a $14.00 price objective on Neos Therapeutics and gave the company a “buy” rating in a report on Saturday, March 17th. Finally, BMO Capital Markets cut Neos Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 31st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the stock. Neos Therapeutics presently has an average rating of “Hold” and an average price target of $15.00.
Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings data on Thursday, March 15th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.61) by $0.12. The firm had revenue of $7.79 million during the quarter, compared to the consensus estimate of $9.30 million. Neos Therapeutics had a negative net margin of 264.80% and a negative return on equity of 437.92%. research analysts forecast that Neos Therapeutics will post -1.53 earnings per share for the current year.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.